OBJECTIVE: To systematically evaluate the efficacy and safety of cefoperazone sulbactam in the treatment of obstetrics and gynecological infections. METHODS: The Cochrane Library

PubMed

Embase

CNKI and Wanfang Data till Jun. 2021 were retrieved to collect randomized controlled trial（RCT） of cefoperazone sulbactam in the treatment of obstetrics and gynecological infections（the observation group was treated with cefoperazone sulbactam

while the control group received ceftazidime）. According to inclusion and exclusion criteria

data were extracted

and methodological quality was evaluated by two researchers. Meta-analysis was performed by using RevMan 5.3 software

and the effect values were odds ratio（OR） and 95%CI. RESULTS: Eight RCT with a total of 1 527 patients were finally included in the literature. Meta-analysis showed that the total effective rate of the observation group was higher than that of the control group（OR=4.09

95%CI=2.77-6.06

P<0.000 01）

and the bacterial clearance rate was higher than that of the control group（OR=2.48

95%CI=1.75-3.51

P<0.000 01）

the differences were statistically significant. There was no significant difference in the incidence of adverse drug reactions between the observation group and control group（OR=0.69

95%CI=0.45-1.04

P=0.08）. CONCLUSIONS: The efficacy of cefoperazone sulbactam in the treatment of obstetrics and gynecological infections is significant with higher safety.